Dr. Anna Pavlick on Options for First-Line Therapy in Late-Stage Melanoma

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Cancer Network spoke with Anna Pavlick, MD, of NYU's Perlmutter Cancer Center, regarding whether there is one correct answer to front-line therapy for the treatment of advanced melanoma.

Cancer Network spoke with Anna Pavlick, MD, medical oncologist at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, regarding whether there is one correct answer to front-line therapy for the treatment of late-stage melanoma. Pavlick presented on this topic during an educational session at ASCO 2019.

Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Related Content
Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.

Encorafenib Combo May Limit Recurrence Risk in BRAF V600+ Melanoma

Ashley Chan
June 12th 2025
Article

Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

RP1/Nivolumab Combo Shows Responses in Advanced Pretreated Melanoma

Ashley Chan
June 8th 2025
Article

Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Roman Fabbricatore
June 5th 2025
Article

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma

No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma

Kristi Rosa
June 3rd 2025
Article

Compared with nivolumab alone, nivolumab/relatlimab did not improve RFS in patients with resected stage III to IV melanoma.